Clinical Trials

33 enrolled

Urinary Bladder Neoplasms

NCT07466238 2026-03-12

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Not yet recruiting

40 enrolled

Biliary Tract Neoplasms

NCT07447076 2026-03-03

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

29 enrolled

Rhabdoid Tumor

NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

106 enrolled

Pancreatic cancer, adult

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT07418931 2026-02-18

CECYDE

108 enrolled

Phase 1 Not yet recruiting

Advanced Squamous Non-Small Cell Lung Cancer

NCT07107750 2026-02-04

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

412 enrolled

Nasopharyngeal Neoplasms

NCT07369791 2026-01-28

NOBLE

76 enrolled

Advanced Biliary Tract Cancer(BTC)

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

418 enrolled

Nasopharyngeal Neoplasms

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2/3 Not yet recruiting

43 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07366840 2026-01-26

BRIGHT

268 enrolled

Breast

Breast Neoplasms

NCT07020065 2026-01-21

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

156 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07353294 2026-01-20

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

12 enrolled

Lymphatic Metastasis

NCT07348107 2026-01-16

ATARI-PDAC

Phase 1 Not yet recruiting

10 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06855225 2026-01-14

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

29 enrolled

Liver Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07272109 2025-12-15

PTCA199-16

210 enrolled

Pancreatic Neoplasms

NCT06177522 2025-11-18

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT06822010 2025-11-14

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

28 enrolled

Urinary Bladder Neoplasms

NCT07189793 2025-09-24

OHAI-NMIBC-01

106 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07184021 2025-09-19

No Acronym

30 enrolled

Urinary Bladder Neoplasms

NCT07158489 2025-09-05

ORIGIN2

47 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

53 enrolled

Nasopharyngeal Carcinoma

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

10 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07109167 2025-08-07

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

30 enrolled

Biliary Tract Neoplasms

NCT07001618 2025-07-23

IMMUNOLIFE2

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07064863 2025-07-17

BCG-TIME

31 enrolled

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT07028424 2025-07-01

PANORAMIX

206 enrolled

PDAC - Pancreatic Ductal Adenocarcinoma

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07003815 2025-06-04

Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer

62 enrolled

Phase 2/3 Not yet recruiting

Biliary Tract Neoplasms

NCT06923475 2025-04-11

NEODISCO

150 enrolled

Cholangiocarcinoma, Klatskin Tumor

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

60 enrolled

Phase 4 Not yet recruiting

Pancreatic Cancer Resectable

NCT06818773 2025-02-10

Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

35 enrolled

Biliary Tract Neoplasms

NCT05562297 2025-01-22

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

50 enrolled

Pancreatic Neoplasms

NCT06274879 2025-01-09

Ablatio

36 enrolled

Bile Duct Neoplasms

NCT06713057 2024-12-03

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

20 enrolled

Thyroid Neoplasms

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06623162 2024-10-04

SASAN-SPARING

70 enrolled

Mibc

NCT06621095 2024-10-01

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

104 enrolled

Pancreatic Neoplasms

NCT06611826 2024-09-25

GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC

41 enrolled

Nasopharyngeal Neoplasms

NCT06591650 2024-09-19

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

GastrointestinalGenitourinary

33 enrolled

Gallbladder Cancer Unresectable

NCT06567600 2024-08-22

Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma

43 enrolled

Cholangiocarcinoma

NCT06513455 2024-07-22

Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

132 enrolled

Pancreatic Neoplasms

NCT06233864 2024-04-17

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

63 enrolled

Pancreatic Neoplasms

NCT06370754 2024-04-17

FD-IMPACT

117 enrolled

Pancreatic Neoplasms

NCT06364826 2024-04-15

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

60 enrolled

Nasopharyngeal Carcinoma

NCT06361030 2024-04-11

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

40 enrolled